GlassScriptPhysician profile
Haiying Cheng
NPI 1689724965
$50,653.48
in general payments reported to CMS, 2019-2025
25 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $2,020 · 2022: $158 · 2023: $16K · 2024: $6,852 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Honoraria: $9,250 · Food and Beverage: $1,201 · Education: $52.50 · Travel and Lodging: $24.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,325.50 |
| Honoraria | $9,250.00 |
| Food and Beverage | $1,200.62 |
| Education | $52.50 |
| Travel and Lodging | $24.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,301.00 | 2019-2023 | Tagrisso |
| Bayer Healthcare Pharmaceuticals INC. | $10,254.14 | 2019-2025 | |
| Fosun Pharma USA INC. | $4,537.53 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,801.80 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $3,316.00 | 2023 | Libtayo |
| Janssen Scientific Affairs, LLC | $3,190.00 | 2021-2023 | Rybrevant |
| G1 Therapeutics, INC. | $3,031.56 | 2023 | Cosela |
| Daiichi Sankyo INC. | $2,450.00 | 2024 | Enhertu |
| Catalyst Pharmaceuticals, INC. | $2,371.59 | 2024 | |
| Genentech USA, INC. | $2,315.17 | 2019-2024 | |
| Novocure INC. | $2,000.00 | 2020 | |
| Medtronic, INC. | $41.07 | 2025 | Osteocool Rf Ablation System |
| Emd Serono, INC. | $16.37 | 2019 | |
| Mirati Therapeutics, INC. | $16.01 | 2023 | Krazati |
| Lilly USA, LLC | $11.24 | 2019 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haiying Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.